首页> 外文期刊>The Journal of Urology >Specific protein patterns characterize metastatic potential of advanced bladder cancer.
【24h】

Specific protein patterns characterize metastatic potential of advanced bladder cancer.

机译:特定的蛋白质模式表征晚期膀胱癌的转移潜力。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: The prognosis in patients with metastasized bladder cancer is still poor. Clinical and histopathological parameters have limited ability to predict the risk of tumor progression. Thus, we identified specific protein patterns associated with tumor progression to differentiate specimens with and without metastasis. MATERIALS AND METHODS: We analyzed 46 metastasized and 42 nonmetastasized muscle invasive bladder cancers by ProteinChip(R) technology surface enhanced laser desorption/ionization time of flight mass spectrometry. Cell lysis was done after laser capture microdissection from cryostat sections to achieve high tumor cell purity. Surface enhanced laser desorption/ionization time of flight mass spectrometry was completed with 2 matrices (Q10 and CM10). Bioinformatic analysis was performed by XLMiner(R) clustering using the Fuzzy c-means method. Differentially expressed proteins were identified and verified by 2-dimensional gel electrophoresis, tryptic in gel digest, peptide mapping, immunodepletion assay and Western blot analysis. RESULTS: By combining data on 2 chip surfaces (Q10 and CM10) results showed 86% sensitivity and 89% specificity in the training set, and 63% sensitivity and 88% specificity in the validation set. The relevant protein peaks 10.83, 14.68, 16.15 and 27.85 Da were identified as S100A8, MAP-1LC3, MUC-1S1 and GST-M1, respectively. CONCLUSIONS: We defined specific protein patterns with ProteinChip technology using bioinformatic evaluation software, which allowed differentiation between nonmetastasized and metastasized bladder tumor samples with high sensitivity and specificity. We identified 4 differentially expressed proteins. Thus, it seems possible to identify patients at high metastasized risk even at a clinically localized stage, leading to individual therapy decisions.
机译:目的:转移性膀胱癌患者的预后仍然很差。临床和组织病理学参数预测肿瘤进展风险的能力有限。因此,我们确定了与肿瘤进展相关的特定蛋白质模式,以区分有无转移的标本。材料与方法:我们通过ProteinChip(R)技术表面增强的激光解吸/电离飞行时间质谱分析了46例转移的和42例未转移的肌肉浸润性膀胱癌。从低温恒温器切片进行激光捕获显微切割后进行细胞裂解,以实现高肿瘤细胞纯度。表面增强的激光解吸/电离飞行时间质谱仪使用2个矩阵(Q10和CM10)完成。生物信息学分析是使用Fuzzy c-means方法通过XLMiner聚类进行的。通过二维凝胶电泳,凝胶消化中的胰蛋白酶消化,肽图分析,免疫耗竭测定和蛋白质印迹分析来鉴定和验证差异表达的蛋白质。结果:通过组合两个芯片表面(Q10和CM10)上的数据,结果显示训练集中的灵敏度为86%,特异性为89%,而验证集中的灵敏度为63%,特异性为88%。相关的蛋白质峰10.83、14.68、16.15和27.85 Da被分别鉴定为S100A8,MAP-1LC3,MUC-1S1和GST-M1。结论:我们使用生物信息学评估软件通过ProteinChip技术定义了特定的蛋白质模式,从而可以高灵敏度和特异性区分未转移和转移的膀胱肿瘤样品。我们鉴定了4种差异表达的蛋白质。因此,即使在临床定位阶段,也似乎有可能鉴定出具有高转移风险的患者,从而导致个体化治疗决策。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号